KRAS and familial pancreatic carcinoma: By using an alternative approach of choking its critical signaling bottleneck at the most downstream signaling hub, we aim to shut down oncogenic K-RAS hyperactivation, inhibit PDAC regrowth, prevent pancreatic cancer cell dissemination, and impede its systemic spread in vitro and in vivo (Figure 1).